Introduction
Action myoclonus-renal failure syndrome (AMRF) is considered a rare form of progressive myoclonic epilepsy (PME) associated with renal dysfunction. It was first described by Andermann in 1986 1 and it was initially believed to be confined to French
Canadians. Nowadays it is recognized as having a more extensive ethnic and geographic distribution including German, Cuban, Australian American and Portuguese patients. [2] [3] [4] Mutations in lysosomal integral membrane protein type 2 (LIMP-2) gene (SCARB2) were recently associated with AMRF by two independent studies. 3, 4 We report the clinical features of two siblings with PME and nephrotic syndrome whose genetic alteration in SCARB2 gene was previously described by Balreira in 2008. 3 LIMP-2 is considered a sorting receptor for the lysosomal hidrolase bglucocerebrosidase (GCase), 5 the enzyme that is deficient in the majority of Gaucher's disease (GD) patients. 6 These patients present a cell type specific deficiency of GCase (normal activity in leukocytes and deficient activity in cultured skin fibroblasts) without any alteration in the gene encoding for GCase (GBA gene). 3 The hypothesis of glucosylceramide storage in central and/or peripheral nervous system, as a consequence of the secondary biochemical defect was raised. In order to try to overcome the pathologic effect of the glycosphingolipids storage, substrate reduction therapy (SRT) with Miglustat
1
, the inhibitor of glucosylceramide synthesis, was assayed in one patient. This paper presents a detailed clinical report of these two siblings and the results obtained with the experimental STR.
Case report
Two female siblings, from a northern Portuguese family are described. The parents were consanguineous and an older sister was healthy.
Patient 1 started having myoclonic jerks during active movements of the upper limbs at the age of 15, with insidious progression of intensity and extension to the lower limbs and trunk, which led to gait instability. Slow horizontal saccadic eye movements were observed at the age of 18. At 20, she was totally dependent, unable to write, to eat independently, to walk and presented a blurred speech with swallowing difficulties. When the patient was 21, she began having edemas in both lower limbs that became generalised with bilateral pleural effusions. Blood pressure was always within the normal range. An increase in body temperature, predominantly in the evening, was observed even in the absence of evidence of systemic infections. She was treated with valproic acid (maximum dose 3900 mg/day), clonazepam (maximum dose 8 mg/day), and piracetam (maximum dose 48 mg/ day). A slight but transient reduction of myoclonus was observed Seizure 20 (2011) [738] [739] [740] Action myoclonus-renal failure syndrome (AMRF) is considered a rare form of progressive myoclonus epilepsy (PME) associated with renal failure. A mutation on the gene encoding the lysosomal integral membrane protein type 2-LIMP-2 (SCARB2), the receptor responsible for targeting glucocerebrosidase to the lysosomes, was recently described, allowing a better understanding of its etiopathogenesis.
We describe clinically two sisters with AMRF that resulted from a mutation in the SCARB2 gene. The renal involvement was due to nephropathy C1q. When substrate-reduction therapy, to correct the possible glucocerebroside storage in the cells with glucocerebrosidase deficiency, was administered to one of the siblings, a significant improvement was observed. This report points out a rational for a therapeutical approach to this new lysossomopathy.
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with every increase in antimyoclonic doses. At the age of 22, she started enzymatic replacement therapy (ERT) with Imiglucerase 1 , 60 U/Kg every two weeks for a year, without improvement. No cognitive decline was observed. She died of septicemia with multiorgan failure at the age of 23.
Patient 2 started with the same type of symptoms when she was 17 years old and the same pattern of progression was documented. She had generalised hyperhidrosis. Similar to her sister, she presented slow horizontal saccades at the age of 20. She became totally dependent and presented edemas at the age of 22. Blood pressure was also always within normal limits. A hyperthermia predominantly in the evening not related to systemic infections was also registered. She was treated with valproic acid (maximum dose 3500 mg/day), clonazepam (maximum dose 12 mg/day), phenobarbitone (maximum dose 300 mg/ day), topiramate (maximum dose 500 mg/day), piracetam (maximum dose 36 mg/day), and levetiracetam (maximum dose 3000 mg/day) with initial but transient benefit. At the age 21, she started ERT with Imiglucerase 1 , 60 U/kg every two weeks for a year with no improvement. At the age of 24, she began SRT with Miglustat 1 (600 mg/daily). At this stage she was completely dependent; had instability of the limbs and trunk due to myoclonic jerks; was unable to seat in the wheelchair; a nasogastric tube was used for feeding; and had anarthria. With SRT, there was a significant reduction on myoclonic jerks and the nasogastric tube was removed. She regained the capacity to seat and eat orally. An improvement in speech was also observed, she was able to produce words again. No intellectual impairment was detected. Despite the continuous and sustained clinical improvement observed for almost 2 years, she died of pneumonia at the age of 26.
Investigation
Patients' brain MRI was normal. The routine EEG showed normal background with generalized paroxysms of spike and polispikes and waves mainly in the posterior regions with the eyes closed during intermittent photostimulation. A giant potential was obtained in somatosensory evoked potential in patient 2.
Toracic, abdominopelvic CT and transthoracic echocardiogram were normal. Renovesical ultrasonographies were normal including the size of kidneys.
At the age of 18, proteinuria of 1 g/24 h was detected in patient 1. When she was 21, she developed normocytic normochromic anemia, thrombocytopenia, hypoalbuminemia and nephrotic proteinuria. At 18, patient 2 developed proteinuria that became nephrotic at 21. At 23, patient 2 developed normocytic normochromic anemia without thrombocytopenia and hypoalbuminemia. At the age of 24, since she was treated with SRT, her renal function was always normal and proteinuria levels did not increase.
Lipids, renal, hepatic function and coagulation tests were normal. In a series of immunological studies only an increase in acute phase proteins and the presence of circulating immunocomplexes were observed. The cellular immunophenotype (T, B and NK populations) in peripheral blood and platelet function studies were normal.
Patient 1 underwent a renal biopsy. Light microscopy study revealed extensive tubular abnormalities with isometric vacuolization in distal and collecting tubules, presence of granular material in cortical tubules without inflammatory infiltration deposits and absence of Gaucher cells. No glomeruli were observed due to technical reasons. Immunofluorescence microscopy (IF) showed a marked deposition of C1q (Fig. 1), IgM (Fig. 2) , and irregular moderated deposits of C3 (Fig. 3) in capillary loops. Patient 1 underwent a bone marrow biopsy which was normal with absence of Gaucher cells.
Light and ultrastructural studies of skin biopsy were normal. Muscle biopsy was normal with normal activity of the analysed mitochondrial enzymes. Cariotype was normal. There was no evidence of DNA mitochondrial alteration: Myoclonic Epilepsy with Ragged Red Fibers mutations A8344G and T8356C were not found. The most common genetic mutations for UnverrichtLundborg disease were also excluded.
Patients' serum lactate, pyruvate, urinary oligosaccharides, arilsulfatase A, total b-hexosaminidase, b-hexosaminidase A, bgalactosidase and a-neuraminidase activity determined in cultured fibroblasts were normal. GCase in cultured skin fibroblasts was deficient (about 10% of controls mean) with a normal activity in leukocytes. Plasmatic acid phosphatase and chitotriosidase activities were normal. No mutations in GBA gene were found but when SCARB2 gene was analysed, a nonsense mutation was identified. Further investigation showed that besides lacking immunodectectable LIMP-2, patients' fibroblasts had also mislocated and decreased amounts of GCase. 
Discussion
We describe two siblings with LIMP-2 deficiency due to a homozygous mutation on SCARB2 gene, whose deficiency was recently established as responsible for AMRF.
3,4 LIMP-2 is the specific binding partner of GCase, the enzyme defective in GD. LIMP-2 was proposed to bind GCase in the endoplasmic reticulum and to escort the enzyme to late endosomes/lysosomes, where dissociation occurs. 5 The deficient GCase activity in patients fibroblasts led us to suspect initially of a juvenile neuronopathic form of GD, however in contrast with GD patients, GCase activity in leukocytes was normal, the activity of plasmatic chitotriosidase was not increased, our patients did not have visceromegaly or cognitive decline and did not have ''Gaucher cells'' in kidney and bone marrow biopsies. No kidney visible storage was detected. In our case, renal involvement was due to a C1q nephropathy, which can be presented as focal segmental sclerosis in light microscopy. 7 In fact, Badhwar 2 described a collapsing glomerulopathy with focal glomeruloclerosis in AMRF syndrome. Unfortunately, no glomeruli were present in sections for light microscopy analysis. C1q nephropathy is a peculiar form of glomerulonephritis characterized by mesangial immunoglobulin and complement deposits, predominantly C1q, with no evidence of systemic lupus erythematosus. C1q nephropathy is a rare condition associated with a wide spectrum of diseases. It remains unclear whether the deposition of C1q in the glomeruli is the response to the deposition of immunoglobulin or immune complex, or whether deposition is a non-specific trapping that accompanies increased glomerular protein trafficking associated with proteinuria. Not only the pathogenesis of C1q deposition in glomeruli, but also its significance are still uncertain. 8 A very different renal involvement has been described in LIMP-2 deficient mice, with dilatation of the renal pelvis and calyces due to massive accumulation of vesicular structures of lysosomal origin which causes obstruction of the urinary tract that leads to hydronephrosis. 9 There are recent reports of patients with PME due to SCARB2 mutation but without any evidence of renal failure. 10 The identification of the mutation in the gene encoding LIMP-2 and the mechanism involved in this novel lysosomal disorder may support why ERT with recombinant GlcCerase (Cerezyme 1 ) was unsuitable to our patients. However, despite of SRT (Miglustat 1 ) was initiated in patient 2 in a very late stage of the disease, a significant and sustained clinical improvement was observed. SRT aims to reduce the rate of glycosphingolipid biosynthesis in order to decrease the amounts of glycosphingolipid storage. It consists of oral administration of N-butyldeoxynojirimycin (NB-DNJ). NB-DNJ are iminosugars extracted from plants and microorganisms, that inhibit the enzyme glucosylceramide synthase (E.C. 2.4.1.80), which catalyzes the first step in GSL biosynthesis: the transfer of glucose from UDP-glucose to ceramide to form glucosylceramide (Platt, 2001 ). NB-DNJ are small molecules with capacity to cross the blood brain barrier and with potential to be effective in lysosomal storage disorders with neurological involvement. There are reports of improvements of neurological manifestations in GD type III patient 11 and Nieman Pick type C. 12 Our clinical data suggest that STR seems to improve the quality of life of these patients, and we believe it ought to be tried in the early stages of the disease. However, more studies are needed to prove the efficacy of this therapy in LIMP-2 deficient patients with secondary deficiency in glucocerebrosidase. This new lysosomal storage disease with SCARB2/LIMP-2 mutation must be considered in every patient with PME without cognitive decline with or without renal involvement in which a cause cannot be identified.
